Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accounts Payables (2020 - 2023)

Cullinan Therapeutics has reported Accounts Payables over the past 4 years, most recently at $951000.0 for Q3 2023.

  • Quarterly results put Accounts Payables at $951000.0 for Q3 2023, down 60.44% from a year ago — trailing twelve months through Sep 2023 was $951000.0 (down 60.44% YoY), and the annual figure for FY2022 was $2.7 million, down 16.06%.
  • Accounts Payables for Q3 2023 was $951000.0 at Cullinan Therapeutics, down from $2.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for CGEM hit a ceiling of $9.7 million in Q4 2020 and a floor of $951000.0 in Q3 2023.
  • Median Accounts Payables over the past 4 years was $2.5 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in Accounts Payables: soared 105.23% in 2022 and later plummeted 67.79% in 2023.
  • Cullinan Therapeutics' Accounts Payables stood at $9.7 million in 2020, then tumbled by 67.26% to $3.2 million in 2021, then decreased by 16.06% to $2.7 million in 2022, then plummeted by 64.25% to $951000.0 in 2023.
  • The last three reported values for Accounts Payables were $951000.0 (Q3 2023), $2.4 million (Q2 2023), and $2.0 million (Q1 2023) per Business Quant data.